![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 26, 2013 11:21:42 AM
Based on prevalence of diabetes here and worldwide , the price tag on an an insulin clone could surpass all the other biosimilar antibodies combined.
After Sanofi, Lilly, and Novo, Viropro would be the first company ever to bioengineer insulin analgues and market them. Even after patent expiration of all Lilly and Novo insulins, no company has been able to clone them.
I wish the company revealed more about its insulin capabilities. They have mentioned only snippets of info about its insulin program. Any one knows more?
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM